San Francisco (Union Square)
Call 844.867.8444 to book an appointment
Dr. Galicki is a Board Certified psychiatrist who specializes in the treatment of mood and anxiety disorders and impact of social, psychological and behavioral factors on general health and quality of life. She has a strong academic and psychopharmacologic background as well as extensive training in various modalities of psychotherapy.
Dr. Galicki is an experienced and empathetic practitioner dedicated to helping her patients understand their mental health conditions and find appropriate treatments. She is humbled to walk the path to wellness with her patients, and help them transform their lives.
When she’s not working with patients, Dr. Galicki enjoys traveling, skiing, reading fiction, and attending live concerts.
Dr. Galicki earned a Medical Degree from Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. She completed her general psychiatry residency followed by a fellowship in Psychosomatic Medicine, at St. Luke’s-Roosevelt Medical Center, a training hospital of Columbia University College of Physicians and Surgeons in New York City.
Dr. Galicki continued on as a staff psychiatrist at St. Luke’s, where she ran the Consult Liaison service, as well as taught and supervised psychiatry residents and fellows. She has also conducted research and published papers on topics including treatment for depression in patients with Parkinson’s disease and Alzheimer’s disease prevention.
After moving to San Francisco in 2011, Dr. Galicki provided outpatient psychiatric care to diverse populations in community clinic and private practice settings. She decided to offer TMS therapy to patients upon seeing its remarkable effects on those who had not responded to other therapies. Dr. Galicki joined TMS Health Solutions in 2016 and is certified in TMS.
Ho L., Spielman L., Petrescu (Galicki) O., Haroutunian V., Purohit D., Czernik A., Yemul S., Aisen P., Mohs R. and Pasinetti G. M.
Altered expression of A-type but not B-type synapsin isoform in the brain of cases at high risk for Alzheimer’s Disease assessed by DNA microarray. Neurosci Letter 298: 191-194 (2001).
Mirjany M., Ho L., Petrescu (Galicki) O., Ionescu A. and Pasinetti G. M.
Excitotoxicity but not â-amyloid toxicity recapitulates changes in gene expression in the brain of cases at high risk of Alzheimer’s Disease dementia. Poster. Soc. Neuroscience Meet. (2001).
Ferrando S. J., Barnhill J. W., Findler M. N., Godbold J., Veytsman M. D., Petrescu (Galicki) O., Marinelli L., Hesketh D., Scarano A., Mor N., Dalton A., Nasser S. and Di Rocco A.
Characterization of depression subtypes in Parkinson’s Disease. Poster. Parkinson’s Disease Conference (2004).